Introduction {#jcmm12764-sec-0001}
============

Hereditary haemochromatosis is an autosomal recessive disease, the principal pathogenic gene of which is HFE [1](#jcmm12764-bib-0001){ref-type="ref"}, [2](#jcmm12764-bib-0002){ref-type="ref"}. The condition is characterized by a disorder of intestinal iron absorption that causes progressive accumulation of iron in organs including the liver, heart and pancreas, leading to their dysfunction [3](#jcmm12764-bib-0003){ref-type="ref"}. An important pathogenic mechanism may the catalytic activity of iron in the formation of hydroxyl radicals. Iron may also suppress host defence cell activity and promote cancer cell proliferation. It is increasingly reported that two mutations in HFE -- C282Y (rs1800562G\>A) and H63D (rs1799945 C\>G) -- are associated with an increased risk of cancers, including hepatocellular [4](#jcmm12764-bib-0004){ref-type="ref"}, [5](#jcmm12764-bib-0005){ref-type="ref"}, breast [6](#jcmm12764-bib-0006){ref-type="ref"}, colorectal [7](#jcmm12764-bib-0007){ref-type="ref"} and prostate cancer [8](#jcmm12764-bib-0008){ref-type="ref"}, as well as others [9](#jcmm12764-bib-0009){ref-type="ref"}, [10](#jcmm12764-bib-0010){ref-type="ref"}, [11](#jcmm12764-bib-0011){ref-type="ref"}, [12](#jcmm12764-bib-0012){ref-type="ref"}. However, some other studies have shown no association between haemochromatosis genotype and neoplasia [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [15](#jcmm12764-bib-0015){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}. This controversy warrants further studies.

In 1996, C282Y and H63D were shown to be related to altered iron status [17](#jcmm12764-bib-0017){ref-type="ref"}. The damage caused by iron overload is associated with oxidative stress, and several studies have demonstrated iron overload to be correlated with carcinogenesis [18](#jcmm12764-bib-0018){ref-type="ref"}. A number of studies have investigated the association between C282Y and H63D and an increased cancer risk. However, the studies have been underpowered and the findings have proved somewhat controversial. For, a meta‐analysis in 2010 by Jin *et al*. [4](#jcmm12764-bib-0004){ref-type="ref"} found a significant association between C282Y and H63D and hepatocellular carcinoma. However, they included a cross‐sectional [19](#jcmm12764-bib-0019){ref-type="ref"}. Moreover, there are now a number of other studies reported [14](#jcmm12764-bib-0014){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [21](#jcmm12764-bib-0021){ref-type="ref"}, [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"}. In 2013, Chen *et al*. reported a significant association between C282Y and colorectal cancer. They only used a recessive model and classified all those from the United States as Caucasians [24](#jcmm12764-bib-0024){ref-type="ref"}. In the same year, Liu *et al*. reported similar findings. They classified those from the United States and Brazil as being Europeans [25](#jcmm12764-bib-0025){ref-type="ref"}.

In our study, we have employed cumulative analysis, which has not been previously used. To the best of our knowledge, this is the most comprehensive meta‐analysis of C282Y and H63D HFE mutations and the risk of cancer. We included 36 studies, comprising 13,680 cases and 73,348 controls. The malignancies studied were principally hepatocellular, breast, colorectal and prostate carcinomas and acute leukaemia.

Materials and methods {#jcmm12764-sec-0002}
=====================

Study identification and selection criteria {#jcmm12764-sec-0003}
-------------------------------------------

We searched PubMed, Embase, the ISI Web of Knowledge, the Chinese Biomedical database and the China National Knowledge Infrastructure to identify relevant studies, from which only case--control and cohort studies published between December 1995 and May 2014 were selected. The terms 'Case--Control Studies or Cohort Studies', 'Neoplasms or Carcinoma', 'Alleles or SNP or Genetic Variation or Mutation or Polymorphism' and 'Haemochromatosis or HFE or C282Y or H63D' were combined. The reference lists and related articles were also scrutinized to identify additional studies.

This study was performed according to the Newcastle--Ottawa Scale (NOS) for meta‐analysis of observational studies [26](#jcmm12764-bib-0026){ref-type="ref"}. The NOS uses a star system (range, 0--9 stars) for evaluating the quality of such studies, allowing a mean value of included studies to be calculated. Articles were selected if they met all of the following criteria: (*i*) the study was a case--control study or cohort study concerning the association between the haemochromatosis genotype C282Y or H63D and risk of cancer; (*ii*) the articles provided data on the distribution of the alleles, the size of the sample and number of controls, the exact number of each genotype or other information to aid the calculations; (*iii*) neoplasms were diagnosed by histopathological biopsy and the controls were free from cancer; and (*iv*) the publication language was English or Chinese. The control group included in our study were hospitalized controls or randomly selected from a pool of eligible participants matched to the index case by age, sex and township of residence.

Data extraction {#jcmm12764-sec-0004}
---------------

Two authors (Yang‐fan Lv and Xian Chang) extracted information independently from the selected studies. The results were compared and collated, and contradictions were resolved by discussion or by consultation with the corresponding author of the study in question. The data extracted were: first author name; title of article; publication year; country where study was performed; territory of participants; HFE mutation type; precise size of case and control groups; and distribution of genotypes in both case and control groups.

Statistical methods {#jcmm12764-sec-0005}
-------------------

The control groups of all of the included articles were tested for Hardy--Weinberg equilibrium [27](#jcmm12764-bib-0027){ref-type="ref"}. The strength of the association between HFE genotypes and cancer risk was measured by the odds ratio (OR) with 95% confidence intervals (CIs). *P* ~OR~ \< 0.05 was regarded as statistically significant. Subgroup meta‐analyses were performed according to cancer type and territory for both C282Y and H63D, independently. The chi‐squared test and *I* ^2^ statistic were used to evaluate heterogeneity [28](#jcmm12764-bib-0028){ref-type="ref"}. *P*‐values less than 0.10 indicated heterogeneity among studies and a random‐effects model was used to estimate the pooled OR. Otherwise, a fixed‐effects model was used. Sensitivity analysis was performed to evaluate the impact of the studies and the stability of the results. To investigate the dynamic trend of the association between HFE mutation and cancer risk, cumulative analysis was performed according to year of publication and sample size [29](#jcmm12764-bib-0029){ref-type="ref"}. Furthermore, Begg\'s test [30](#jcmm12764-bib-0030){ref-type="ref"} and Egger\'s test [31](#jcmm12764-bib-0031){ref-type="ref"} were performed to assess the publication bias of the literature [30](#jcmm12764-bib-0030){ref-type="ref"}, [32](#jcmm12764-bib-0032){ref-type="ref"}. *P* \< 0.05 was considered statistically significant. All statistical tests were performed with STATA 12.0 software [31](#jcmm12764-bib-0031){ref-type="ref"}. Finally, to adjust for multiple comparisons, the Bonferroni method were applied (see Tables S1 and S2).

Results {#jcmm12764-sec-0006}
=======

Eligible studies {#jcmm12764-sec-0007}
----------------

One hundred and twenty‐nine studies were found concerning the association between HFE mutation and cancer risk. Following a review of all articles according to the criteria (shown in Fig. [1](#jcmm12764-fig-0001){ref-type="fig"}), 36 eligible studies were included in our pooled analysis. Among these, 33 [7](#jcmm12764-bib-0007){ref-type="ref"}, [8](#jcmm12764-bib-0008){ref-type="ref"}, [10](#jcmm12764-bib-0010){ref-type="ref"}, [12](#jcmm12764-bib-0012){ref-type="ref"}, [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [15](#jcmm12764-bib-0015){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [21](#jcmm12764-bib-0021){ref-type="ref"}, [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"}, [33](#jcmm12764-bib-0033){ref-type="ref"}, [34](#jcmm12764-bib-0034){ref-type="ref"}, [35](#jcmm12764-bib-0035){ref-type="ref"}, [36](#jcmm12764-bib-0036){ref-type="ref"}, [37](#jcmm12764-bib-0037){ref-type="ref"}, [38](#jcmm12764-bib-0038){ref-type="ref"}, [39](#jcmm12764-bib-0039){ref-type="ref"}, [40](#jcmm12764-bib-0040){ref-type="ref"}, [41](#jcmm12764-bib-0041){ref-type="ref"}, [42](#jcmm12764-bib-0042){ref-type="ref"}, [43](#jcmm12764-bib-0043){ref-type="ref"}, [44](#jcmm12764-bib-0044){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, [46](#jcmm12764-bib-0046){ref-type="ref"}, [47](#jcmm12764-bib-0047){ref-type="ref"}, [48](#jcmm12764-bib-0048){ref-type="ref"}, [49](#jcmm12764-bib-0049){ref-type="ref"}, [50](#jcmm12764-bib-0050){ref-type="ref"}, [51](#jcmm12764-bib-0051){ref-type="ref"}, [52](#jcmm12764-bib-0052){ref-type="ref"}, [53](#jcmm12764-bib-0053){ref-type="ref"} were concerned with C282Y, 30 [6](#jcmm12764-bib-0006){ref-type="ref"}, [7](#jcmm12764-bib-0007){ref-type="ref"}, [8](#jcmm12764-bib-0008){ref-type="ref"}, [9](#jcmm12764-bib-0009){ref-type="ref"}, [10](#jcmm12764-bib-0010){ref-type="ref"}, [12](#jcmm12764-bib-0012){ref-type="ref"}, [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"}, [38](#jcmm12764-bib-0038){ref-type="ref"}, [39](#jcmm12764-bib-0039){ref-type="ref"}, [40](#jcmm12764-bib-0040){ref-type="ref"}, [41](#jcmm12764-bib-0041){ref-type="ref"}, [42](#jcmm12764-bib-0042){ref-type="ref"}, [43](#jcmm12764-bib-0043){ref-type="ref"}, [44](#jcmm12764-bib-0044){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, [46](#jcmm12764-bib-0046){ref-type="ref"}, [47](#jcmm12764-bib-0047){ref-type="ref"}, [48](#jcmm12764-bib-0048){ref-type="ref"}, [49](#jcmm12764-bib-0049){ref-type="ref"}, [50](#jcmm12764-bib-0050){ref-type="ref"}, [51](#jcmm12764-bib-0051){ref-type="ref"}, [52](#jcmm12764-bib-0052){ref-type="ref"}, [53](#jcmm12764-bib-0053){ref-type="ref"} with H63D and 27 [7](#jcmm12764-bib-0007){ref-type="ref"}, [8](#jcmm12764-bib-0008){ref-type="ref"}, [10](#jcmm12764-bib-0010){ref-type="ref"}, [12](#jcmm12764-bib-0012){ref-type="ref"}, [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [15](#jcmm12764-bib-0015){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"}, [38](#jcmm12764-bib-0038){ref-type="ref"}, [39](#jcmm12764-bib-0039){ref-type="ref"}, [40](#jcmm12764-bib-0040){ref-type="ref"}, [41](#jcmm12764-bib-0041){ref-type="ref"}, [42](#jcmm12764-bib-0042){ref-type="ref"}, [43](#jcmm12764-bib-0043){ref-type="ref"}, [44](#jcmm12764-bib-0044){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, [46](#jcmm12764-bib-0046){ref-type="ref"}, [47](#jcmm12764-bib-0047){ref-type="ref"}, [48](#jcmm12764-bib-0048){ref-type="ref"}, [49](#jcmm12764-bib-0049){ref-type="ref"}, [50](#jcmm12764-bib-0050){ref-type="ref"}, [51](#jcmm12764-bib-0051){ref-type="ref"}, [52](#jcmm12764-bib-0052){ref-type="ref"}, [53](#jcmm12764-bib-0053){ref-type="ref"} with both C282Y and H63D. The principal characteristics of the studies concerning C282Y and H63D are listed in Tables [1](#jcmm12764-tbl-0001){ref-type="table-wrap"} and [2](#jcmm12764-tbl-0002){ref-type="table-wrap"}. It should be noted that one study [56](#jcmm12764-bib-0056){ref-type="ref"} was excluded because it did not provide sufficient data of the distribution of genotypes in both case and control groups.

![Flow chart for inclusion of studies.](JCMM-20-1219-g001){#jcmm12764-fig-0001}

###### 

Main characteristics of all case--control or cohort studies included in H63D and cancer risk

  First author      Year   Study design    Country          Territory        Cancer type      Sample size   Case   Control                      
  ----------------- ------ --------------- ---------------- ---------------- ---------------- ------------- ------ --------- ----- ----- ------ --------
  Beckman           1999   Case--control   Sweden           European         Breast           165/294       1      25        139   4     35     255
  Altes             1999   Case--control   France           European         Colorectal       73/76         0      5         68    0     6      70
  Beckman           1999   Case--control   Sweden           European         Colorectal       173/294       2      21        150   4     35     255
  Gimferrer         1999   Case--control   Spain            European         AL               36/106        0      3         33    0     6      100
  Racchi            1999   Case--control   Italy            European         Hepatocellular   15/130        0      3         12    0     11     119
  Beckman           2000   Case--control   Sweden           European         Hepatocellular   54/294        1      10        43    1     38     255
  Parkkila          2001   Case--control   Finland          European         AL               18/102        0      0         18    0     10     92
  Fargion           2001   Case--control   Italy            European         Hepatocellular   81/128        0      7         74    0     2      126
  Campo S           2001   Case--control   Italy            European         Hepatocellular   23/304        0      0         23    0     1      303
  Lauret            2002   Case--control   Spain            European         Hepatocellular   77/359        0      12        65    0     22     337
  Boige             2003   Case--control   France           European         Hepatocellular   133/100       0      7         126   1     6      93
  Cauza             2003   Case--control   Australia        Oceanican        Hepatocellular   162/671       5      18        139   5     63     603
  Shaheen           2003   Case--control   United States    North American   Colorectal       475/833       0      44        431   3     68     762
  Hellerbrand       2003   Case--control   Germany          European         Hepatocellular   137/233       0      17        120   0     10     223
  van der           2003   Case--control   Netherlands      European         Colorectal       191/573       0      16        175   3     38     532
  Kallianpur        2004   Cohort          United States    North American   Breast           41/129        5      10        26    7     15     107
  Abraham           2005   Case--control   Germany          European         Breast           566/649       2      59        505   1     71     577
  McGlynn           2005   Case--control   United States    North American   Colorectal       635/650       5      70        560   3     76     571
  Robinson          2005   Case--control   United Kingdom   European         Colorectal       327/322       2      50        275   4     39     279
  Shi               2005   Case--control   China            Asian            Hepatocellular   56/60         6      3         47    0     1      59
  Festa             2005   Case--control   Sweden           European         Basal cell       241/259       2      17        222   1     22     236
  Syrjakoski        2006   Cohort          Finland          European         Prostatic        843/480       9      55        779   3     45     432
  Syrjakoski        2006   Cohort          Finland          European         Breast           116/480       1      5         110   3     45     432
  Cardoso           2006   Case--control   Portugal         European         Cervical         150/91        0      14        136   1     5      85
  Kondrashova       2006   Case--control   Russia           European         Breast           100/260       0      2         98    0     17     243
  Ropero            2007   Case--control   Spain            European         Hepatocellular   196/181       1      12        183   0     23     158
  Yonal             2007   Case--control   Turkey           Asian            Hepatocellular   19/251        0      0         19    2     2      247
  Hucl              2007   Case--control   Germany          European         Pancreatic       117/428       1      7         109   1     30     397
  Nahon             2008   Cohort          France           European         Hepatocellular   103/198       0      12        91    0     18     180
  Ezzikouri         2008   Case--control   France           European         Hepatocellular   96/222        0      2         94    0     3      219
  Shi               2009   Case--control   Australia        Oceanica         Colorectal       85/3079       0      16        69    16    424    2639
  Shi               2009   Case--control   Polish           European         Colorectal       75/1622       0      1         74    2     123    1497
  Osborne           2010   Cohort          Australia        Oceanican        Colorectal       620/28,414    10     80        530   193   3882   24,339
  Osborne           2010   Cohort          Australia        Oceanican        Breast           664/16,399    9      90        565   90    2263   14,046
  Gannon            2011   Cohort          Canada           North American   Ovarian          354/80        2      32        320   0     2      78
  Ekblom            2012   Cohort          Sweden           European         Colorectal       211/400       2      27        182   1     47     352
  Rodriguez‐Lopez   2013   Case--control   Spain            European         AL               59/173        0      2         57    0     16     157
  Total                                                                                       7487/59,324                                       

C indicates C282Y mutant and W indicates wild‐type respectively, AL indicates acute leukaemia.
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###### 

Main characteristics of all case--control or cohort studies included in H63D and cancer risk

  First author      Year   Study design    Country          Territory        Cancer type      Sample size   Case   Control                    
  ----------------- ------ --------------- ---------------- ---------------- ---------------- ------------- ------ --------- ----- ---- ----- ------
  Racci             1999   Case--control   Italy            European         Hepatocellular   12/130        0      3         9     3    42    85
  Gimferrer         1999   Case--control   Spain            European         AL               36/106        2      11        23    2    28    76
  Altes             1999   Case--control   France           European         Colorectal       110/100       6      36        68    2    28    70
  Beckman           2000   Case--control   Sweden           European         Hepatocellular   54/294        0      17        37    6    59    229
  Campo S           2001   Case--control   Italy            European         Hepatocellular   23/304        1      6         16    12   90    202
  Martinez          2001   Case--control   Italy            European         Gliomas          174/144       6      56        112   2    32    110
  Lauret            2002   Case--control   Spain            European         Hepatocellular   77/359        0      25        52    33   92    234
  Boige             2003   Case--control   France           European         Hepatocellular   133/100       0      41        92    1    40    59
  Cauza             2003   Case--control   Australia        Oceanican        Hepatocellular   162/671       3      31        128   9    133   529
  Shaheen           2003   Case--control   United States    North American   Colorectal       475/833       10     88        377   12   135   686
  Hellerbrand       2003   Case--control   Germany          European         Hepatocellular   137/233       2      27        108   4    52    177
  Abraham           2005   Case--control   Germany          European         Breast           571/646       12     138       421   16   173   457
  McGlynn           2005   Case--control   United States    North American   Colorectal       662/650       13     164       485   15   146   489
  Robinson          2005   Case--control   United Kingdom   European         Colorectal       327/322       8      83        236   8    73    241
  Shi               2005   Case--control   China            Asian            Hepatocellular   56/60         2      4         50    1    3     56
  Gunel‐Ozcan       2006   Case--control   Turkey           Asian            Breast           88/100        0      39        49    1    26    73
  Syrjakoski        2006   Cohort          Finland          European         Prostatic        843/480       17     177       649   7    88    385
  Syrjakoski        2006   Cohort          Finland          European         Breast           116/480       9      26        89    7    88    385
  Cardoso           2006   Case--control   Portugal         European         Cervical         185/135       6      43        136   6    46    85
  Kondrashova       2006   Case--control   Russica          European         Breast           99/260        2      30        67    5    75    180
  Yonal             2007   Case--control   Turkey           Asian            Hepatocellular   19/251        2      6         11    4    61    186
  Hucl              2007   Case--control   Germany          European         Pancreatic       158/549       3      46        109   8    144   397
  Ropero            2007   Case--control   Spain            European         Hepatocellular   196/181       9      85        102   5    52    124
  Ezzikouri         2008   Case--control   France           European         Hepatocellular   96/226        3      34        59    2    60    160
  Nahon             2008   Cohort          France           European         Hepatocellular   103/198       0      28        75    0    49    149
  Shi               2009   Case--control   Australia        Oceanican        Colorectal       78/2614       1      18        59    63   732   1819
  Shi               2009   Case--control   Australia        Oceanican        Colorectal       70/1605       4      15        51    40   402   1163
  Batschauer        2011   Case--control   Brazil           South American   Breast           68/85         6      13        49    3    25    57
  Gannon            2011   Cohort          Canada           North American   Ovarian          354/80        8      92        254   3    17    60
  Gannon            2011   Cohort          Canada           North American   Endometrial      111/80        4      36        71    3    17    60
  Ekblom            2012   Cohort          Sweden           European         Colorectal       218/414       5      42        171   13   96    305
  Agudo             2013   Case--control   Spain            European         Gastric          323/1158      11     82        230   23   249   885
  Rodriguez‐Lopez   2013   Case--control   Spain            European         AL               59/179        1      9         49    5    60    114
  Total                                                                                       6193/14,024                                     

H indicates H63D mutant and W indicates wild‐type respectively. AL indicates acute leukaemia.

John Wiley & Sons, Ltd

Meta‐analysis results {#jcmm12764-sec-0008}
---------------------

### C282Y {#jcmm12764-sec-0009}

The principal findings for C282Y came from 37 data sets from 33 studies, comprising 7487 cases and 59,324 controls (Table [1](#jcmm12764-tbl-0001){ref-type="table-wrap"}). Six studies concerned breast cancer [8](#jcmm12764-bib-0008){ref-type="ref"}, [33](#jcmm12764-bib-0033){ref-type="ref"}, [34](#jcmm12764-bib-0034){ref-type="ref"}, [36](#jcmm12764-bib-0036){ref-type="ref"}, [41](#jcmm12764-bib-0041){ref-type="ref"}, [51](#jcmm12764-bib-0051){ref-type="ref"}, nine colorectal cancer [7](#jcmm12764-bib-0007){ref-type="ref"}, [15](#jcmm12764-bib-0015){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}, [33](#jcmm12764-bib-0033){ref-type="ref"}, [36](#jcmm12764-bib-0036){ref-type="ref"}, [40](#jcmm12764-bib-0040){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, [46](#jcmm12764-bib-0046){ref-type="ref"}, [48](#jcmm12764-bib-0048){ref-type="ref"}, thirteen hepatocellular carcinoma [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [21](#jcmm12764-bib-0021){ref-type="ref"}, [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"}, [38](#jcmm12764-bib-0038){ref-type="ref"}, [39](#jcmm12764-bib-0039){ref-type="ref"}, [43](#jcmm12764-bib-0043){ref-type="ref"}, [49](#jcmm12764-bib-0049){ref-type="ref"}, [50](#jcmm12764-bib-0050){ref-type="ref"}, [52](#jcmm12764-bib-0052){ref-type="ref"}, [53](#jcmm12764-bib-0053){ref-type="ref"} and eight studies included six other types of cancer [8](#jcmm12764-bib-0008){ref-type="ref"}, [10](#jcmm12764-bib-0010){ref-type="ref"}, [12](#jcmm12764-bib-0012){ref-type="ref"}, [35](#jcmm12764-bib-0035){ref-type="ref"}, [37](#jcmm12764-bib-0037){ref-type="ref"}, [42](#jcmm12764-bib-0042){ref-type="ref"}, [44](#jcmm12764-bib-0044){ref-type="ref"}, [47](#jcmm12764-bib-0047){ref-type="ref"} including basal cell carcinoma, cervical cancer, prostatic carcinoma, pancreatic carcinoma, acute leukaemia and ovarian carcinoma. Twenty‐seven studies were European [7](#jcmm12764-bib-0007){ref-type="ref"}, [8](#jcmm12764-bib-0008){ref-type="ref"}, [12](#jcmm12764-bib-0012){ref-type="ref"}, [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [15](#jcmm12764-bib-0015){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [21](#jcmm12764-bib-0021){ref-type="ref"}, [33](#jcmm12764-bib-0033){ref-type="ref"}, [35](#jcmm12764-bib-0035){ref-type="ref"}, [37](#jcmm12764-bib-0037){ref-type="ref"}, [38](#jcmm12764-bib-0038){ref-type="ref"}, [41](#jcmm12764-bib-0041){ref-type="ref"}, [42](#jcmm12764-bib-0042){ref-type="ref"}, [43](#jcmm12764-bib-0043){ref-type="ref"}, [44](#jcmm12764-bib-0044){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, [46](#jcmm12764-bib-0046){ref-type="ref"}, [47](#jcmm12764-bib-0047){ref-type="ref"}, [48](#jcmm12764-bib-0048){ref-type="ref"}, [49](#jcmm12764-bib-0049){ref-type="ref"}, [50](#jcmm12764-bib-0050){ref-type="ref"}, [51](#jcmm12764-bib-0051){ref-type="ref"}, [52](#jcmm12764-bib-0052){ref-type="ref"}, [53](#jcmm12764-bib-0053){ref-type="ref"}, three Oceanian [36](#jcmm12764-bib-0036){ref-type="ref"}, [39](#jcmm12764-bib-0039){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, four North American [10](#jcmm12764-bib-0010){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}, [34](#jcmm12764-bib-0034){ref-type="ref"}, [40](#jcmm12764-bib-0040){ref-type="ref"} and two Asian [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"}. Overall, a significantly elevated cancer risk was found according to a recessive genetic model [57](#jcmm12764-bib-0057){ref-type="ref"} (OR: 1.991, 95% CI: 1.448--2.737) and an allele model [53](#jcmm12764-bib-0053){ref-type="ref"} (OR: 1.116, 95% CI: 1.024--1.217) (Fig. [2](#jcmm12764-fig-0002){ref-type="fig"}), whereas no statistically significant difference was found in a dominant model [57](#jcmm12764-bib-0057){ref-type="ref"} (OR: 1.088, 95% CI: 0.992--1.193). Moderate heterogeneity was detected in the dominant model (*P* ~h~ = 0.004, *I* ^2^ = 42.3%) and the allele model (*P* ~h~ = 0.003, *I* ^2^ = 43.1%), but there was zero heterogeneity in the recessive model (*P* ~h~ = 0.632, *I* ^2^ = 0.0%).

![Forest plot (fixed‐effects model) showed C282Y was associated with increased cancer risk in an allele model. Each study is shown by the point estimate of the OR (the size of the square is proportional to the weight of each study) and 95% CI for the OR (extending lines).](JCMM-20-1219-g002){#jcmm12764-fig-0002}

On subgroup analysis stratified by cancer type (Table [3](#jcmm12764-tbl-0003){ref-type="table-wrap"}), statistically significantly elevated cancer risk was detected in a recessive model for breast cancer (OR: 2.143, 95% CI: 1.24--3.697), hepatocellular carcinoma (OR: 3.642, 95% CI: 1.454--9.122) and colorectal carcinoma (OR: 1.692, 95% CI: 1.041--2.750). The other cancer types showed no significantly increased risk. On subgroup analysis stratified by territory (Table [3](#jcmm12764-tbl-0003){ref-type="table-wrap"}), significantly increased risk of cancer was demonstrated in the Oceanian study population in a recessive model (OR: 2.558, 95% CI: 1.657--3.949), in the Asian population in an allele model (OR: 6.975, 95% CI: 1.315--36.999) with significant heterogeneity and in the Asian population in the dominant model (OR: 5.622, 95% CI: 1.014--31.178). No increased cancer risk was found in either European or North American study populations in any genetic model. Heterogeneity was not observed or was slight in all studies, except in an Asian population using an allele model (*P* ~h~ = 0.106, *I* ^2^ = 61.7%).

###### 

Pooled analysis of association of C282Y and cancer risk

                   Case/control   Dominant model          Recessive model   Allele model                                                                           
  ---------------- -------------- ----------------------- ----------------- -------------- ----------------------- ------- ------- ----------------------- ------- --------
  Total            7487/59,324    1.088 (0.992--1.193)    0.004             42.30%         1.991 (1.448--2.737)    0.811   0.00%   1.116 (1.024--1.217)    0.003   43.10%
  Cancer type                                                                                                                                                      
  Breast           1652/18,211    1.046 (0.884--1.236)    0.031             59.40%         2.143 (1.242--3.697)    0.673   0.00%   1.091 (0.934--1.274)    0.025   61.20%
  Colorectal       2865/36,263    1.062 (0.927--1.216)    0.77              0.00%          1.692 (1.041--2.750)    0.523   0.00%   1.073 (0.946--1.219)    0.852   0.00%
  Hepatocellular   1152/3131      1.574 (1.217--2.036)    0.016             51.40%         3.642 (1.454--9.122)    0.568   0.00%   1.608 (1.263--2.049)    0.01    54.10%
  Others           1818/1719      0.874 (0.662--1.152     0.252             22.30%         1.546 (0.593--4.031)    0.724   0.00%   0.920 (0.709--1.194)    0.324   13.60%
  Territory                                                                                                                                                        
  European         4376/8758      1.057 (0.921--1.213)    0.01              42.90%         1.255 (0.702--2.244)    0.831   0.00%   1.059 (0.929--1.207)    0.026   37.70%
  Oceanican        1531/48,563    1.083 (0.937--1.251)    0.46              0.00%          2.558 (1.657--3.949)    0.795   0.00%   1.142 (1.000--1.305)    0.373   4.00%
  Asian            75/311         5.622 (1.014--31.178)   0.261             20.90%         6.647 (0.807--54.756)   0.402   0.00%   6.975 (1.315--36.999)   0.106   61.70%
  North American   1505/1692      1.166 (0.917--1.482)    0.029             66.80%         1.682 (0.721--3.923)    0.572   0.00%   1.183 (0.944--1.482)    0.017   70.40%
  Begg                            *P* = 0.367             *P* = 0.216       *P* = 0.425                                                                            
  Egger                           *P* = 0.217             *P* = 0.100       *P* = 0.334                                                                            

*P* ~h~: test for heterogeneity, OR: odds ratio, CI: confidence interval.

*I* ^2^: the percentage of total variation across studies that is a result of heterogeneity rather than chance.

C indicates C282Y mutant and W indicates wild‐type respectively.
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### H63D {#jcmm12764-sec-0010}

The results for H63D are comprised of 33 data sets extracted from 30 studies with 6193 cases and 14,024 controls (listed in Table [2](#jcmm12764-tbl-0002){ref-type="table-wrap"}). Twelve studies were concerned with hepatocellular carcinoma [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"}, [38](#jcmm12764-bib-0038){ref-type="ref"}, [39](#jcmm12764-bib-0039){ref-type="ref"}, [43](#jcmm12764-bib-0043){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, [49](#jcmm12764-bib-0049){ref-type="ref"}, [50](#jcmm12764-bib-0050){ref-type="ref"}, [52](#jcmm12764-bib-0052){ref-type="ref"}, [53](#jcmm12764-bib-0053){ref-type="ref"}, two with acute leukaemia [12](#jcmm12764-bib-0012){ref-type="ref"}, [47](#jcmm12764-bib-0047){ref-type="ref"}, seven with colorectal cancer [7](#jcmm12764-bib-0007){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}, [40](#jcmm12764-bib-0040){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, [46](#jcmm12764-bib-0046){ref-type="ref"}, [48](#jcmm12764-bib-0048){ref-type="ref"}, five with breast cancer [6](#jcmm12764-bib-0006){ref-type="ref"}, [8](#jcmm12764-bib-0008){ref-type="ref"}, [41](#jcmm12764-bib-0041){ref-type="ref"}, [51](#jcmm12764-bib-0051){ref-type="ref"}, [55](#jcmm12764-bib-0055){ref-type="ref"} and seven with other neoplasms including glioma [54](#jcmm12764-bib-0054){ref-type="ref"}, prostatic cancer [8](#jcmm12764-bib-0008){ref-type="ref"}, cervical cancer [42](#jcmm12764-bib-0042){ref-type="ref"}, pancreatic cancer [44](#jcmm12764-bib-0044){ref-type="ref"}, ovarian cancer [10](#jcmm12764-bib-0010){ref-type="ref"}, endometrial cancer [10](#jcmm12764-bib-0010){ref-type="ref"} and gastric carcinoma [9](#jcmm12764-bib-0009){ref-type="ref"}. Twenty‐two studies were European [7](#jcmm12764-bib-0007){ref-type="ref"}, [8](#jcmm12764-bib-0008){ref-type="ref"}, [9](#jcmm12764-bib-0009){ref-type="ref"}, [12](#jcmm12764-bib-0012){ref-type="ref"}, [13](#jcmm12764-bib-0013){ref-type="ref"}, [14](#jcmm12764-bib-0014){ref-type="ref"}, [20](#jcmm12764-bib-0020){ref-type="ref"}, [38](#jcmm12764-bib-0038){ref-type="ref"}, [41](#jcmm12764-bib-0041){ref-type="ref"}, [42](#jcmm12764-bib-0042){ref-type="ref"}, [43](#jcmm12764-bib-0043){ref-type="ref"}, [44](#jcmm12764-bib-0044){ref-type="ref"}, [46](#jcmm12764-bib-0046){ref-type="ref"}, [47](#jcmm12764-bib-0047){ref-type="ref"}, [48](#jcmm12764-bib-0048){ref-type="ref"}, [49](#jcmm12764-bib-0049){ref-type="ref"}, [50](#jcmm12764-bib-0050){ref-type="ref"}, [51](#jcmm12764-bib-0051){ref-type="ref"}, [52](#jcmm12764-bib-0052){ref-type="ref"}, [53](#jcmm12764-bib-0053){ref-type="ref"}, [54](#jcmm12764-bib-0054){ref-type="ref"}, four were North American [10](#jcmm12764-bib-0010){ref-type="ref"}, [16](#jcmm12764-bib-0016){ref-type="ref"}, [40](#jcmm12764-bib-0040){ref-type="ref"}, three were Oceanian [39](#jcmm12764-bib-0039){ref-type="ref"}, [45](#jcmm12764-bib-0045){ref-type="ref"}, three were Asian [6](#jcmm12764-bib-0006){ref-type="ref"}, [22](#jcmm12764-bib-0022){ref-type="ref"}, [23](#jcmm12764-bib-0023){ref-type="ref"} and one was South American [55](#jcmm12764-bib-0055){ref-type="ref"}. Overall, unlike C282Y, no significant increase in cancer risk was found in any genetic model (Table [4](#jcmm12764-tbl-0004){ref-type="table-wrap"}). No heterogeneity (*P* ~h~ = 0.754, *I* ^2^ = 0.0%) was found in the recessive model (Fig. [3](#jcmm12764-fig-0003){ref-type="fig"}); the other two models showed significant heterogeneity (dominant -- *P* ~h~ = 0.002, *I* ^2^ = 46.7%; allele -- *P* ~h~ = 0.002, *I* ^2^ = 47.2%).

###### 

Pooled analysis of association of H63D and cancer risk

                   Case/Control   Dominant model         Recessive model   Allele model                                                                           
  ---------------- -------------- ---------------------- ----------------- -------------- ----------------------- ------- -------- ---------------------- ------- --------
  Total            6193/14,024    1.107 (1.025--1.196)   0.002             46.70%         1.215 (0.966--1.528)    0.754   0.00%    1.095 (1.023--1.172)   0.002   47.20%
  Cancer type                                                                                                                                                     
  Breast           942/1571       1.014 (0.841--1.221)   0.072             53.50%         0.996 (0.555--1.788)    0.629   0.00%    1.010 (0.857--1.191)   0.2     33.20%
  Colorectal       1940/6538      1.065 (0.929--1.221)   0.339             11.90%         1.152 (0.781--1.699)    0.496   0.00%    1.064 (0.942--1.202)   0.252   23.20%
  Hepatocellular   1068/3003      1.169 (0.988--1.383)   0.051             43.90%         1.447 (0.828--2.529)    0.321   12.90%   1.126 (0.971--1.306)   0.017   52.20%
  AL               95/285         0.681 (0.395--1.175)   0.013             83.80%         1.447 (0.333--6.289)    0.279   14.70%   0.785 (0.486--1.268)   0.01    84.80%
  Others           2148/2627      1.212 (1.048--1.402)   0.048             52.70%         1.278 (0.844--1.934)    0.719   0.00%    1.191 (1.047--1.355)   0.053   51.70%
  Territory                                                                                                                                                       
  European         4050/6995      1.089 (0.992--1.195)   0.001             55.70%         1.162 (0.872--1.549)    0.783   0.00%    1.074 (0.989--1.167)   0.001   57.10%
  Oceanican        310/4890       0.907 (0.685--1.200)   0.654             0.00%          1.590 (0.742--3.405)    0.411   0.00%    0.960 (0.748--1.232)   0.464   0.00%
  Asian            163/411        2.066 (1.280--3.334)   0.946             0.00%          3.147 (0.853--11.612)   0.268   24.00%   1.880 (1.248--2.832)   0.868   0.00%
  North American   1602/1643      1.187 (1.001--1.408)   0.683             0.00%          0.986 (0.603--1.611)    0.669   0.00%    1.147 (0.984--1.336)   0.697   0.00%
  South American   68/85          0.789 (0.393--1.584)                                    2.645 (0.636--10.994)                    1.010 (0.564--1.809)           
  Begg                            *P* = 0.963            *P* = 0.466       *P* = 0.963                                                                            
  Egger                           *P* = 0.987            *P* = 0.526       *P* = 0.995                                                                            

*P* ~h~: test for heterogeneity, OR: odds ratio, CI: confidence interval.

*I* ^2^: the percentage of total variation across studies that is a result of heterogeneity rather than chance.

H indicates H63D mutant and W indicates wild‐type respectively.

John Wiley & Sons, Ltd

![Forest plot (fixed‐effects model) indicated H63D was not associated with increased cancer risk in a recessive model. Each study is shown by the point estimate of the OR combined with 95% CI for the OR. % weight represents the weight of each study.](JCMM-20-1219-g003){#jcmm12764-fig-0003}

Subgroup meta‐analysis was performed according to cancer type and territory. For cancer type, elevated cancer risk was detected in a dominant model for 'others', with moderate heterogeneity (*P* ~h~ = 0.048, *I* ^2^ = 52.7%). Given that 'others' included several types of cancer and that heterogeneity was significant, this result should be viewed with caution. No significantly elevated cancer risk was detected in any other genetic model, suggesting that H63D is not associated with these types of cancer. For territory, increased cancer risk was found in the Asian study population in a dominant model (OR: 2.066, 95% CI: 1.280--3.334, *P* ~h~ = 0.946) and an allele model (OR: 1.880, 95% CI: 1.248--2.832, *P* ~h~ = 0.868), both with no heterogeneity (*I* ^2^ = 0.0%). In the European, North American, Oceanian and South American populations, no significantly elevated cancer risk was detected in any genetic model.

Publication bias and sensitivity analysis {#jcmm12764-sec-0011}
-----------------------------------------

For C282Y, funnel plots and Begg\'s and Egger\'s test were performed to analyse for publication bias in all three genetic models. The shapes of the funnel plots (Fig. [4](#jcmm12764-fig-0004){ref-type="fig"}) appeared symmetrical, indicating no statistically significantly publication bias for the association between C282Y and risk of cancer. This was in agreement with the results from Begg\'s and Egger\'s tests (Table [3](#jcmm12764-tbl-0003){ref-type="table-wrap"}). Similarly, there was no evidence of publication bias for H63D (Table [4](#jcmm12764-tbl-0004){ref-type="table-wrap"}). All of these results indicate that the findings of our study were robust.

![Funnel plot illustrating publication bias (recessive model of C282Y polymorphism).](JCMM-20-1219-g004){#jcmm12764-fig-0004}

Sensitivity analysis [58](#jcmm12764-bib-0058){ref-type="ref"} was conducted to determine the publication bias and influence of each study on the pooled OR by sequentially omitting individual studies from the analysis. The series of pooled ORs with 95% CIs lies not far from the midline for the C282Y mutation, which means that the statistical findings were not materially altered by the elimination of any study in the recessive model (Fig. [5](#jcmm12764-fig-0005){ref-type="fig"}). Thus, the possible positive association between C282Y and cancer risk was stable, especially for breast cancer, colorectal cancer and hepatocellular carcinoma.

![Analysis of the influence of summary odds ratio coefficients on the association between C282Y mutation and cancer risk in the recessive model.](JCMM-20-1219-g005){#jcmm12764-fig-0005}

Similar results were achieved in the sensitivity analysis for H63D mutation, confirming the stability of our findings for H63D.

Cumulative analysis {#jcmm12764-sec-0012}
-------------------

Cumulative meta‐analysis [29](#jcmm12764-bib-0029){ref-type="ref"} was performed by sorting studies by chronological order and sample size. This allows the stability of the research findings over time to be explored. As shown in Figure [6](#jcmm12764-fig-0006){ref-type="fig"}, there is a tendency towards a positive association between C282Y and cancer risk with time. Simultaneously, 95% CIs became narrower, indicating improved precision and accuracy. Increasing sample sizes also narrowed the 95% CIs; the implications being similar.

![Forest plots for cumulative meta‐analysis of the association between C282Y and cancer risk in the recessive model (year of publication).](JCMM-20-1219-g006){#jcmm12764-fig-0006}

Discussion {#jcmm12764-sec-0013}
==========

In this compound study, we performed a meta‐analysis of the association between mutations of the HFE gene and risk of cancer including 36 eligible case--control or cohort studies. Thirty‐three studies concerned the C282Y mutation, with 7487 cases and 59,324 controls. C282Y was found to increase the risk of cancer twofold in the recessive model and 1.1‐fold in the allele mode. On stratified analysis by cancer type, a statistically significant increase was found for breast cancer, colorectal cancer and hepatocellular carcinoma in the recessive model, in accordance with the studies of Jin *et al*. [4](#jcmm12764-bib-0004){ref-type="ref"}, Chen *et al*. [24](#jcmm12764-bib-0024){ref-type="ref"} and Liu *et al*. [25](#jcmm12764-bib-0025){ref-type="ref"}. These results suggest that the C282Y/C282Y genotype is associated with a twofold elevated risk for breast cancer, a 1.7‐fold elevated risk of colorectal, and a 3.6‐fold increased risk of hepatocellular cancer. There is insufficient evidence to conclude that it is a risk factor for other types of cancer. Subgroup analysis stratified by territory showed that the C282Y mutation was associated with a 2.6‐fold increased risk of cancer in Oceanian populations in a recessive model and by 6.9‐fold in Asian populations in an allele model. These findings suggest that the living environment, genetic background and dietary habits are candidate factors that influence the risk of cancer because of HFE mutations. This is the most comprehensive study reported to date, evaluating the association between HFE genotype and overall cancer risk, with stratification based on territory.

H63D, another missense mutation of the *HFE* gene, was investigated in thirty studies with 6193 cases and 14,024 controls. We found that H63D did not increase the overall cancer risk or the risk of particular types of cancer on subgroup analysis, with ORs only slightly over 1 in all genetic models. However, the result of 'others' showed H63D increased cancer risk 1.2‐fold in both dominant and allele models. Given that 'others' included several types of cancer, and that the heterogeneity in both model was moderate, we advise that these findings should be viewed with caution. Our results indicated that H63D is a weak or irrelevant factor in the development of cancer. However, in the Asian study population, H63D was found to be related to elevated cancer risk in both a dominant by twofold and an allele model by 1.9‐fold, suggesting a possible role for genetic background, diet and lifestyle, and environmental conditions.

Generally, it could be concluded from our study that the C282Y mutation, especially the C82Y/C282Y genotype, is a risk factor for cancer. The association between C282Y and breast, colorectal and hepatocellular carcinoma was statistically significant. However, H63D was not a distinct risk factor or only a weak one. It is well known that HFE is an atypical major histocompatibility complex class I molecule, affecting iron load and immune function through its interaction with β2 microglobulin (β2 m) and the TfRs (TfR1 and TfR2) [59](#jcmm12764-bib-0059){ref-type="ref"}, [60](#jcmm12764-bib-0060){ref-type="ref"}. Generally, normal HFE associates with β2 m, transits to the membrane, and binds with TfRs. When combining with TfR1, HFE competes with transferrin to limit the rate of iron uptake, promoting a homoeostatic level of iron load. However, when forming a complex with TfR2, it stimulates the secretion of Hepcidin, thus suppressing the iron export protein ferroportin and promoting cells to retain iron intracellularly. All these finding indicated that HFE plays vital role in iron homoeostasis regulation [61](#jcmm12764-bib-0061){ref-type="ref"}. Expectedly, mutations in HFE cause the disruption of HFE function, leading to iron overload. Specifically, C282Y polymorphism cannot interact with β2 m, preventing its surface translocation and variant H63D translocates to the cell surface but fails to participate in the interactions with the TfR1, which might promote the interaction with TfR2 in hepatocytes, causing a systemic increase in hepcidin and suppression of ferroportin [59](#jcmm12764-bib-0059){ref-type="ref"}, [62](#jcmm12764-bib-0062){ref-type="ref"}.

The mechanism of the damage caused by excess iron might be related to the creation of free radicals during the Fenton reaction, leading to the formation of reactive oxygen species (ROSs). It is known that ROSs can cause lipid peroxidation, protein modification, and DNA and RNA mutations, thus resulting in dysregulation of normal cell functioning, pathological states and cell death [63](#jcmm12764-bib-0063){ref-type="ref"}, [64](#jcmm12764-bib-0064){ref-type="ref"}. Specifically, intracellular iron overload leads to cell cycle arrest at the G1/S stage by affecting the expression of certain cyclins and protein kinases. Reactive oxygen species can react with DNA, causing damage, mutation, oncogene activation or inactivation of cancer suppressor genes. In addition, hydroxyl radicals may cause apoptosis [65](#jcmm12764-bib-0065){ref-type="ref"} because of their effects on mitochondrial and lysosomal membranes.

As suggested by the American Association for the Study of Liver Diseases, phlebotomy is the principle treatment for hereditary haemochromatosis, being an effective method for maintaining serum ferritin levels. Thus, a number of the cases included in our study had probably undergone phlebotomy, which would have reduced their serum ferritin levels and might have reduced their susceptibility to cancer. This may have affected the results of our study.

Our study has limitations. First, our meta‐analysis was based on unadjusted related data, and any confounding factors could not be controlled for because most of the included studies did not provide any relevant data. Second, the sample sizes of several of the studies might not have been large enough to detect any possible risks associated with the HFE mutations. This is most likely to have applied to the results concerning Oceanian and Asian populations. Third, because cancer is a complex disease with a multifactorial aetiology, gene--gene and gene--environment interactions should be evaluated; however, we did not address this in our study. Last, most of the studies included in our meta‐analysis were concerned with breast cancer, colorectal cancer or hepatocellular carcinoma; those concerning several other types of cancer were simply combined together as 'others'. As a consequence, our findings with these studies might not be precise. We hope to address this in future studies.

In conclusion, this is a comprehensive meta‐analysis concerning HFE gene mutation (C282Y and H63D) and overall cancer risk. The C282Y mutation was associated with increased overall cancer susceptibility, especially for hepatocellular carcinoma, breast cancer and colorectal cancer, whereas the H63D mutation produced non‐significant results for these three types of cancer. The effect of territory on the association between HFE mutation and cancer could be a factor in susceptibility. Further well‐designed epidemiological studies of cancer types and territory and large‐scale studies concerning gene--gene or gene--environment interactions should be conducted to clarify the association. The molecular mechanism of how C282Y increases cancer risk also merits further study, to aid understanding of the role of HFE gene mutation in carcinogenesis.
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